333 related articles for article (PubMed ID: 27696202)
21. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
[TBL] [Abstract][Full Text] [Related]
22. Expression of programmed death-1 in cutaneous extranodal natural killer/T-cell lymphoma and its effect on clinical findings and biological behaviour.
Kim YJ; Won CH; Chang SE; Lee MW; Choi JH; Lee WJ
J Eur Acad Dermatol Venereol; 2017 May; 31(5):821-827. PubMed ID: 28190256
[TBL] [Abstract][Full Text] [Related]
23. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
[TBL] [Abstract][Full Text] [Related]
24. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
[TBL] [Abstract][Full Text] [Related]
25. The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.
Sato Y; Kinoshita M; Takemura S; Tanaka S; Hamano G; Nakamori S; Fujikawa M; Sugawara Y; Yamamoto T; Arimoto A; Yamamura M; Sasaki M; Harada K; Nakanuma Y; Kubo S
Pathol Int; 2017 Mar; 67(3):163-170. PubMed ID: 28139862
[TBL] [Abstract][Full Text] [Related]
26. The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.
Qu QX; Huang Q; Shen Y; Zhu YB; Zhang XG
Tumour Biol; 2016 Apr; 37(4):5031-7. PubMed ID: 26541760
[TBL] [Abstract][Full Text] [Related]
27. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
29. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.
Joseph RW; Millis SZ; Carballido EM; Bryant D; Gatalica Z; Reddy S; Bryce AH; Vogelzang NJ; Stanton ML; Castle EP; Ho TH
Cancer Immunol Res; 2015 Dec; 3(12):1303-7. PubMed ID: 26307625
[TBL] [Abstract][Full Text] [Related]
30. Extranodal natural killer/T-Cell lymphoma: A population-based comparison of sinonasal and extranasal disease.
Vazquez A; Khan MN; Blake DM; Sanghvi S; Baredes S; Eloy JA
Laryngoscope; 2014 Apr; 124(4):888-95. PubMed ID: 24114591
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.
Zhang B; Yu W; Feng X; Zhao Z; Fan Y; Meng Y; Hu S; Cui Y; He Q; Zhang H; Li D; He Z; Zhou L; Jin J; Han W
Med Oncol; 2017 May; 34(5):94. PubMed ID: 28409437
[TBL] [Abstract][Full Text] [Related]
32. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
33. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Paydas S; Bagir EK; Deveci MA; Gonlusen G
Med Oncol; 2016 Aug; 33(8):93. PubMed ID: 27421997
[TBL] [Abstract][Full Text] [Related]
34. Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer.
Toyokawa G; Takada K; Haratake N; Takamori S; Akamine T; Katsura M; Fujishita T; Shoji F; Okamoto T; Oda Y; Maehara Y
Anticancer Res; 2016 Aug; 36(8):4329-36. PubMed ID: 27466552
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological study of pulmonary extranodal nature killer/T-cell lymphoma, nasal type and literature review.
Ding W; Wang J; Zhao S; Yang Q; Sun H; Yan J; Gao L; Yao W; Zhang W; Liu W
Pathol Res Pract; 2015 Jul; 211(7):544-9. PubMed ID: 25953340
[TBL] [Abstract][Full Text] [Related]
36. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
[TBL] [Abstract][Full Text] [Related]
37. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
Cho J; Lee J; Bang H; Kim ST; Park SH; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kang WK; Kim S; Kim KM
Oncotarget; 2017 Feb; 8(8):13320-13328. PubMed ID: 28076847
[TBL] [Abstract][Full Text] [Related]
38. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.
Shi L; Chen L; Wu C; Zhu Y; Xu B; Zheng X; Sun M; Wen W; Dai X; Yang M; Lv Q; Lu B; Jiang J
Clin Cancer Res; 2016 Mar; 22(5):1173-1184. PubMed ID: 26933175
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
40. Programmed Cell Death Ligand 1 Expression in Canine Cancer.
Shosu K; Sakurai M; Inoue K; Nakagawa T; Sakai H; Morimoto M; Okuda M; Noguchi S; Mizuno T
In Vivo; 2016; 30(3):195-204. PubMed ID: 27107075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
